The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT00868478 · UNKNOWN

Trial details

NCT number: NCT00868478
Sponsor: Kaplan Medical Center
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia

Start date: 2009-04-01
Primary completion: 2011-04-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.